Affimed NVNASDAQ:AFMD
- LAST PRICE4.3500
- TODAY'S CHANGE (%)0.2900 (7.1429%)
- Bid / Lots4.3300/ 25
- Ask / Lots4.4000/ 2
- Open / Previous Close4.0600 / 4.0600
- Day Range
- 52 Week Range
- Volume75,746
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AFMD |
|---|---|---|
| 09:36 ET | 100 | 4.06 |
| 09:50 ET | 197 | 4.0104 |
| 09:52 ET | 293 | 4.1 |
| 09:59 ET | 1046 | 4.0101 |
| 10:01 ET | 435 | 4.1 |
| 10:06 ET | 100 | 4.06 |
| 10:10 ET | 1100 | 4.135 |
| 10:12 ET | 794 | 4.08 |
| 10:21 ET | 3472 | 4.095 |
| 10:28 ET | 100 | 4.095 |
| 10:39 ET | 800 | 4.12 |
| 10:44 ET | 230 | 4.1432 |
| 10:53 ET | 306 | 4.15 |
| 11:09 ET | 700 | 4.1591 |
| 11:11 ET | 1158 | 4.16 |
| 11:15 ET | 1132 | 4.14 |
| 11:26 ET | 1000 | 4.2 |
| 11:29 ET | 453 | 4.0925 |
| 11:40 ET | 200 | 4.19 |
| 11:49 ET | 400 | 4.15 |
| 11:54 ET | 300 | 4.16 |
| 12:00 ET | 100 | 4.15 |
| 12:09 ET | 100 | 4.15 |
| 12:23 ET | 201 | 4.15 |
| 12:25 ET | 2831 | 4.1599 |
| 12:27 ET | 4130 | 4.24 |
| 12:30 ET | 2954 | 4.3 |
| 12:32 ET | 300 | 4.3 |
| 12:34 ET | 289 | 4.35 |
| 12:36 ET | 2191 | 4.2902 |
| 12:38 ET | 2877 | 4.2801 |
| 12:39 ET | 2040 | 4.2401 |
| 12:48 ET | 700 | 4.21 |
| 12:50 ET | 200 | 4.2 |
| 01:10 ET | 1200 | 4.2 |
| 01:19 ET | 900 | 4.28 |
| 01:24 ET | 100 | 4.3 |
| 01:28 ET | 569 | 4.22 |
| 01:35 ET | 500 | 4.2887 |
| 01:42 ET | 335 | 4.2 |
| 01:44 ET | 300 | 4.22 |
| 01:46 ET | 500 | 4.2581 |
| 01:48 ET | 106 | 4.26 |
| 01:51 ET | 1000 | 4.27 |
| 02:08 ET | 1368 | 4.2201 |
| 02:11 ET | 492 | 4.28 |
| 02:13 ET | 678 | 4.29 |
| 02:15 ET | 3940 | 4.29 |
| 02:18 ET | 1100 | 4.25 |
| 02:20 ET | 1000 | 4.242 |
| 02:27 ET | 600 | 4.2816 |
| 02:36 ET | 100 | 4.29 |
| 02:54 ET | 1000 | 4.265 |
| 03:00 ET | 100 | 4.265 |
| 03:02 ET | 500 | 4.3 |
| 03:03 ET | 699 | 4.275 |
| 03:12 ET | 2508 | 4.2406 |
| 03:16 ET | 3626 | 4.299 |
| 03:18 ET | 700 | 4.26 |
| 03:20 ET | 3600 | 4.25 |
| 03:21 ET | 100 | 4.25 |
| 03:30 ET | 200 | 4.29 |
| 03:32 ET | 404 | 4.255 |
| 03:36 ET | 131 | 4.255 |
| 03:41 ET | 400 | 4.255 |
| 03:45 ET | 156 | 4.255 |
| 03:48 ET | 2127 | 4.29 |
| 03:50 ET | 100 | 4.29 |
| 03:54 ET | 100 | 4.3 |
| 03:56 ET | 834 | 4.32 |
| 03:57 ET | 300 | 4.35 |
May 29, 2024
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer, from 6:30AM ET on Wednesday May 29, 2024 by Dow Jones
6:30AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
Affimed Announces Annual General Meeting of Shareholders, from 6:30AM ET on Tuesday May 28, 2024 by Dow Jones
6:30AM ET on Tuesday May 28, 2024 by Dow Jones
May 23, 2024
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024, from 5:05PM ET on Thursday May 23, 2024 by Dow Jones
5:05PM ET on Thursday May 23, 2024 by Dow Jones
May 14, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Affimed NV | 66.2M | -0.6x | --- |
Atara Biotherapeutics Inc | 67.5M | -0.3x | --- |
Curis Inc | 61.1M | -1.2x | --- |
Collplant Biotechnologies Ltd | 64.2M | -8.4x | --- |
Ikena Oncology Inc | 85.4M | -1.1x | --- |
DURECT Corp | 53.1M | -2.0x | --- |
Company Information
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Contact Information
- Headquarters
- Gottlieb-Daimler-Strasse 2MANNHEIM, Germany 68165
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Supervisory Board
- Thomas Hecht
- Chief Executive Officer, Chief Medical Officer, Member of the Management Board
- Andreas Harstrick
- Consulting Chief Financial Officer, Member of the Management Board
- Harry Welten
- Chief Operating Officer, Member of the Management Board
- Wolfgang Fischer
- Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
- Denise Mueller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $66.2M |
|---|---|
Revenue (TTM) | $9.0M |
Shares Outstanding | 15.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.04 |
EPS | $-7.69 |
Book Value | $4.19 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 7.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,288.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
